PHVS

Pharvaris N.V.

• Simply Wall St·1d ago

  Why Pharvaris (PHVS) Is Up 8.6% After Expanding Deucrictibant HAE Data And Regulatory Plans

• TipRanks·1d ago

  Pharvaris Executive Makes Notable Move in Latest Insider Stock Sale

• Simply Wall St·3d ago

  A Look At Pharvaris (PHVS) Valuation As Deucrictibant Data Advances Toward Key EAACI 2026 Catalyst

• TipRanks·6d ago

  Pharvaris management to meet with Oppenheimer

• Seeking Alpha·06/03 13:35

  Most and least shorted mid- to mega-cap healthcare stocks at the end of May

• Simply Wall St·05/31 13:12

  The Bull Case For Pharvaris (PHVS) Could Change Following New Deucrictibant Phase 3 Data Disclosures

• TipRanks·05/29 20:40

  Pharvaris management to meet with Oppenheimer

• PUBT·05/29 10:51

  Pharvaris to present Phase 3 RAPIDe-3 end-of-progression data for oral deucrictibant in hereditary angioedema at EAACI 2026

• TipRanks·05/28 00:43

  Pharvaris Maintained at Buy as Analyst Reaffirms $52 Price Target on Deucrictibant Late-Stage Strength and M&A Optionality

• TipRanks·05/27 02:12

  Top Pharvaris Insiders Quietly Cash Out in Significant Share Sales

• PUBT·05/26 21:46

  Pharvaris Principal Accounting Officer Anna Nijdam disposes of common shares worth $224,207.69

• Simply Wall St·05/23 13:26

  Assessing Pharvaris (PHVS) Valuation After Narrower Quarterly Loss And Shifting Investor Expectations

• PUBT·05/22 18:54

  Pharvaris director Elisabeth Bjork disposes 10,000 common shares for $293,166

• TipRanks·05/20 02:05

  Top Pharvaris Insiders Quietly Cash Out in Major Stock Moves

• PUBT·05/19 22:43

  Pharvaris Chief Commercial Officer Wim Souverijns sells 10,000 shares for $299,163